FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world. 4. November 2022 Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke M; TPK-Group (Tumour Registry Pancreatic Cancer). FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world. Int J Cancer. 2022 FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world. Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke… Weiterlesen Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study. A Jakob, M-O Zahn, A Nusch, T Werner, R Schnell, M Frank, N Hamm, K-U Däßler, C Losem, M Welslau, P Hoevel, K Potthoff, 2022. Weiterlesen